uBriGene Biosciences at ESGCT 2026

Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website

uBriGene Biosciences brings 2 presentations to ESGCT 2026 in Hamburg. Its work covers vectors and reagents for cell therapy. One project generates CAR T cells inside the body using detargeted lentiviral vectors aimed at CD7, and another reprogrammes blood cells into induced pluripotent stem cells with circular RNA in lipid nanoparticles.

OrganizationESGCT 2026 Attendance
ubrigene.com
CDMOs & CROs
Cell and gene therapy CDMO that also provides contract research, analytical testing and ready-to-use research and GMP-grade products.
Poster
Wed Oct 28
1:30pm–3:30pm
High-Yield In Vivo CAR-T Development Enabled by CD7 Nanoboy and Detargeted Cocal-G Lentiviral Vectors
Immunotherapy and CAR T cells
Poster
Thu Oct 29
2:00pm–4:00pm
The Best-in-Class PBMC iPSC Reprogramming Kit via circRNA-LNP
Disease Models
RNA and oligonucleotide therapiesCell therapies and CAR-T

Explore the full ESGCT 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Hamburg. Leave your work email and we’ll be in touch.

Privacy

Download the full ESGCT 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from uBriGene Biosciences

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction